-transparent.png){kind=logo}
Type VI Ehlers-Danlos syndrome is a disease characterized by disturbed lysine hydroxylation of collagen. The disease is caused by mutations in lysyl hydroxylase 1 gene and it affects several organs including the cardiovascular system, the joint and musculoskeletal system, and the skin. The skin of type VI Ehlers-Danlos syndrome patients is hyperelastic, scars easily, and heals slowly and poorly. We hypothesized that providing functional lysyl hydroxylase 1 gene to the fibroblasts in and around wounds in these patients would improve healing. In this study we tested the feasibility of transfer of the lysyl hydroxylase 1 gene into fibroblasts derived from rats and a type VI Ehlers-Danlos syndrome patient (in vitro) and into rat skin (in vivo). We first cloned human lysyl hydroxylase 1 cDNA into a recombinant adenoviral vector (Ad5RSV-LH). Transfection of human type VI Ehlers-Danlos syndrome fibroblasts (about 20% of normal lysyl hydroxylase 1 activity) with the vector increased lysyl hydroxylase 1 activity in these cells to near or greater levels than that of wild type, unaffected fibroblasts. The adenoviral vector successfully transfected rat fibroblasts producing both beta-galactosidase and lysyl hydroxylase 1 gene activity. We next expanded our studies to a rodent model. Intradermal injections of the vector to the abdominal skin of rats produced lysyl hydroxylase 1 mRNA and elevated lysyl hydroxylase 1 activity, in vivo. These data suggest the feasibility of gene replacement therapy to modify skin wound healing in type VI Ehlers-Danlos syndrome patients.
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
September 1989,
The Journal of pediatrics,
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
September 1976,
Archives of ophthalmology (Chicago, Ill. : 1960),
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
November 1992,
Nature genetics,
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
October 1999,
Human mutation,
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
October 1980,
Biochemical and biophysical research communications,
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
February 2000,
Matrix biology : journal of the International Society for Matrix Biology,
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
April 1998,
Archives of dermatological research,
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
November 1997,
Archives of biochemistry and biophysics,
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
April 1994,
The Journal of clinical investigation,
T Rauma, and
S Kumpumäki, and
R Anderson, and
B L Davidson, and
H Ruotsalainen, and
R Myllylä, and
T Hautala
July 1984,
American journal of human genetics,
